YusufSSleightPPogueJ. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000; 342: 145–153.
3.
DahlöfBDevereuxRBKjeldsenSE. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet2002; 359: 995–1003.
SantosRASFerreiraAJSimõesE. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol2008; 93: 519–527.
6.
De CaterinaARHarperARCuculiF. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag2012; 8: 299–305.
7.
BoerrigterGSoergelDGViolinJD. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail2012; 5: 627–634.
MangiaficoSCostello-BoerrigterLCAndersenIA. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J. Epub ahead of print 31August2012.
MiuraSKarnikSS. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens1999; 17: 397–404.
14.
RosenströmUSköldCLindebergG. Synthesis and AT2 receptor-binding properties of angiotensin II analogues. J Pept Res2004; 64: 194–201.
15.
JonesESDel BorgoMPKirschJF. A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function. Hypertension2011; 57: 570–576.
WanYWallinderCPlouffeB. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem2004; 47: 5995–6008.
KaschinaEGrzesiakALiJ. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?Circulation2008; 118: 2523–2532.
20.
JingFMogiMSakataA. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab2012; 32: 248–255.
LulaIDenadaiALResendeJM. Study of angiotensin-(1–7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides2007; 28: 2199–2210.
BalingitPPArmstrongDGReyzelmanAM. NorLeu3-A(1–7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen2012; 20: 482–490.
27.
ShemeshRToporikALevineZ. Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem2008; 283: 34643–34649.
28.
SavergniniSQBeimanMLautnerRQ. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension2010; 56: 112–120.
29.
Compugen, http://cgen.com (2007, accessed 18 September 2012).
